Pharma BD Deal Intelligence
Patheon became the foundation of Thermo Fisher's CDMO platform — a genuine growth engine, not a legacy drag
Full analysis, sources & comparables →Evercore ISI's Ross Muken said the acquisition should help Thermo Fisher achieve a 'multi-year core growth reacceleration,' citing the rapid growth of the CDMO…
Industry observers noted the deal accelerated CDMO consolidation and gave Thermo Fisher a turn-key end-to-end pharma services franchise from API through…
Thermo Fisher's continued investment in pharma services (including a $150M expansion) reinforced the 'golden age for CDMOs' narrative and validated the Patheon…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Thermo Fisher agreed to acquire Patheon for $35.00/share in cash, total enterprise value approximately $7.2B (including ~$2.0B assumed net debt). The deal added a leading pharmaceutical CDMO with $1.9B fiscal 2016 revenue to Thermo Fisher's Laboratory Products and Services Segment, with expected $120M synergies by year three. Closed August 29, 2017.
Patheon became the foundation of Thermo Fisher's CDMO platform — a genuine growth engine, not a legacy drag
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Patheon N.V. (this deal) | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2017 deals · Thermo Fisher Scientific Inc. deals · Other deals